Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4% – What’s Next?

Emergent Biosolutions Inc. (NYSE:EBS)’s share price was down 7.4% on Thursday . The stock traded as low as $11.68 and last traded at $11.61. Approximately 125,997 shares were traded during trading, a decline of 85% from the average daily volume of 866,333 shares. The stock had previously closed at $12.54.

Analyst Ratings Changes

A number of research firms have recently issued reports on EBS. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Emergent Biosolutions in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Monday, December 29th. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Friday, October 24th. Finally, Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 30th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.00.

Emergent Biosolutions Trading Up 0.5%

The company’s 50 day simple moving average is $11.68 and its two-hundred day simple moving average is $9.53. The company has a market capitalization of $577.72 million, a price-to-earnings ratio of 8.46 and a beta of 2.30. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.18. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%.The firm had revenue of $231.10 million during the quarter, compared to analysts’ expectations of $203.67 million. As a group, research analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the sale, the director directly owned 98,417 shares of the company’s stock, valued at $1,178,051.49. This represents a 18.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Emergent Biosolutions

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Emergent Biosolutions during the second quarter valued at $31,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at about $35,000. Raymond James Financial Inc. purchased a new position in shares of Emergent Biosolutions in the 2nd quarter valued at about $53,000. Janney Montgomery Scott LLC acquired a new position in Emergent Biosolutions in the 2nd quarter worth about $68,000. Finally, Baron Wealth Management LLC purchased a new position in Emergent Biosolutions during the fourth quarter worth approximately $133,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.